Cargando…

Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection

BACKGROUND: Hepatitis B surface antigen (HBsAg) is a detectable index after hepatitis B virus (HBV) infection, which is a risk factor of hepatocellular carcinoma (HCC). However, few studies have focused on the expression of HBsAg in HCC patients’ liver tissues. This study aimed to explore the potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Ziming, Chen, Jinbin, Wang, Juncheng, Xu, Li, Zhou, Zhongguo, Chen, Minshan, Zhang, Yaojun, Shi, Mude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2020
Materias:	Original Articles: Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704243/ https://www.ncbi.nlm.nih.gov/pubmed/32049678 http://dx.doi.org/10.1097/MEG.0000000000001698

Ejemplares similares

Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy
por: Zheng, Zhikai, et al.
Publicado: (2023)

The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study
por: Zhang, Yaojun, et al.
Publicado: (2018)

Utilization of hepatitis B surface antigen-positive donors in liver transplantation for recipients with hepatocellular carcinoma: a retrospective and propensity score matching analysis
por: Chen, Zhitao, et al.
Publicado: (2023)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
por: Hu, Zili, et al.
Publicado: (2022)

An integrated strategy for deciding open versus laparoscopic hepatectomy for resectable primary liver cancer
por: Fu, Yizhen, et al.
Publicado: (2023)

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
por: Zhang, Tian-Ying, et al.
Publicado: (2020)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
por: Zhang, Dali, et al.
Publicado: (2022)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy
por: Wu, Tianqing, et al.
Publicado: (2023)

A Nomogram Based on Preoperative Lab Tests, BMI, ICG-R15, and EHBF for the Prediction of Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
por: Zhang, Deyao, et al.
Publicado: (2022)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study
por: Wang, Kun, et al.
Publicado: (2019)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
por: Triantafyllou, Evangelos, et al.
Publicado: (2018)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria
por: Sun, Xuqi, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients
por: Chen, Jinbin, et al.
Publicado: (2017)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

N‐myc and STAT interactor correlates with severity and prognosis in acute‐on‐chronic liver failure of hepatitis B virus
por: Xiong, Lifu, et al.
Publicado: (2019)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
por: Tsai, Yu-Fen, et al.
Publicado: (2019)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Antiviral therapy effectively improves liver hemodynamics as evidenced by serum biomarker and contrast-enhanced ultrasound examinations in patients with hepatitis B cirrhosis
por: Xu, Xiaoyong, et al.
Publicado: (2018)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
por: Allweiss, Lena, et al.
Publicado: (2023)

Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B
por: Jang, Jeong Won
Publicado: (2010)

Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
por: Sun, Xuqi, et al.
Publicado: (2020)

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism
por: Wilhelm, Annika, et al.
Publicado: (2016)

A Retrospective Analysis of COVID-19-infected Patients with Acute Hepatitis who Develop Acute Liver Failure in a Safety Net Hospital
por: Pellegrini Jr., James Robert, et al.
Publicado: (2021)

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
por: Perugorria, Maria J, et al.
Publicado: (2019)

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
por: Esparza-Baquer, Aitor, et al.
Publicado: (2021)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gl5q936lv5uajaepkn20er4quo